{"id":45897,"date":"2022-07-07T08:01:47","date_gmt":"2022-07-07T06:01:47","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/sensorion-to-present-at-the-gene-therapy-neurological-disorders-europe-casss-bioassays-symposium-and-cell-gene-therapy-summit-conferences-in-july-2022\/"},"modified":"2022-07-07T08:01:47","modified_gmt":"2022-07-07T06:01:47","slug":"sensorion-to-present-at-the-gene-therapy-neurological-disorders-europe-casss-bioassays-symposium-and-cell-gene-therapy-summit-conferences-in-july-2022","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/sensorion-to-present-at-the-gene-therapy-neurological-disorders-europe-casss-bioassays-symposium-and-cell-gene-therapy-summit-conferences-in-july-2022\/","title":{"rendered":"Sensorion to Present at the Gene Therapy Neurological Disorders Europe, CASSS Bioassays Symposium and Cell & Gene Therapy Summit Conferences in July 2022"},"content":{"rendered":"
\n

MONTPELLIER, France–(BUSINESS WIRE)–Regulatory News:\n<\/p>\n

\nSensorion (FR0012596468 \u2013 ALSEN) <\/b>a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, is pleased to announce the participation of members of Sensorion\u2019s management in three scientific conferences in July 2022.\n<\/p>\n

\nLaurent Desire, Ph.D., Sensorion\u2019s Preclinical Development Director, will participate, in-person, in a workshop entitled Gene Therapy for Novel indications<\/b>, on July 11, 2022 at the 3rd<\/sup> annual Gene Therapy Neurological Disorders Europe <\/b>meeting, being held in Paris, France, July 11-13, 2022.\n<\/p>\n

\nWorkshop<\/b>: Gene Therapy for Novel indications <\/b>(Laurent Desire\u2019s contribution will focus on the inner ear)
\n
Date<\/b>: Monday, July 11, 2022
\n
Time<\/b>: 5 am \u2013 7 am EDT (11 am \u2013 1 pm CEST)
\n
Presenter<\/b>: Laurent Desire, Ph.D.
\n
Event<\/b>: Gene Therapy Neurological Disorders Europe<\/a>\n<\/p>\n

\nOtmane Boussif, Sc.D., Sensorion\u2019s Chief Technical Officer, will participate virtually in a panel discussion entitled Dealing with Post-Marketing Activities for Cell & Gene Therapy<\/b> on July 19, 2022, at the 7th Cell & Gene Therapy Summit<\/b> on July 19-21, 2022. He will also give a presentation on Advancing Gene Therapy for Hearing Disorders: Dual AAV Manufacturing & Control Strategy<\/b>, on July 21, 2022.\n<\/p>\n

\nPanel Discussion:<\/b> Dealing with Post-Marketing Activities for Cell & Gene Therapy
\n
<\/b>Date: <\/b>Tuesday, July 19, 2022
\n
Time: <\/b>4.20 pm \u2013 5.15 pm SGT (10.20 am \u2013 11.15 am CEST)
\n
Presenter: <\/b>Otmane Boussif, Sc.D.
\n
Event: <\/b>7th Cell & Gene Therapy Summit<\/a>\n<\/p>\n

\nPresentation<\/b>: Advancing Gene Therapy for Hearing Disorders: Dual AAV Manufacturing & Control Strategy
\n
<\/b>Date: <\/b>Thursday, July 21, 2022
\n
Time<\/b>: 3.15 pm \u2013 4 pm SGT (9.15 am \u2013 10 am CEST)
\n
Presenter<\/b>: Otmane Boussif, Sc.D.
\n
Event: <\/b>7th Cell & Gene Therapy Summit<\/a>\n<\/p>\n

\nChristine Le Bec, Ph.D., Sensorion\u2019s Head of CMC Gene Therapy, will give a talk on the Characterization of<\/b> Dual AAV Vector Otoferlin<\/b>, on July 21, 2022, virtually, at the CASSS<\/b> Bioassays Symposium<\/b>, being held in Gaithersburg, MD, USA, July 19-21, 2022.\n<\/p>\n

\nPresentation<\/b>: Characterization of Dual AAV Vector Otoferlin
\n
<\/b>Date<\/b>: Thursday, July 21, 2022
\n
Time<\/b>: 2.40 pm \u2013 3.05 pm EDT (8.40 pm \u2013 9.05 pm CEST)
\n
Presenter<\/b>: <\/b>Christine Le Bec, Ph.D.
\n
Event<\/b>: CASSS Bioassays Symposium<\/a>\n<\/p>\n

\nAbout Sensorion<\/b>\n<\/p>\n

\nSensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, a significant global unmet medical need.\n<\/p>\n

\nSensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and modalities for drug candidates. Its portfolio combines both small molecule programs and a preclinical portfolio of inner ear gene therapies.\n<\/p>\n

\nIts clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a planned Phase 2 Proof of Concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) and, with partner Cochlear Limited, a study of SENS-401 in patients scheduled for cochlear implantation.\n<\/p>\n

\nSensorion has entered into a broad strategic collaboration with Institut Pasteur focused on the genetics of hearing. It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness including deafness caused by a mutation of the gene encoding for Otoferlin, and hearing loss related to mutation in GJB2 gene to potentially address important hearing loss segments in adults and children. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses.\n<\/p>\n

\nwww.sensorion.com<\/a>\n<\/p>\n

\nLabel: SENSORION
\n
<\/b>ISIN: FR0012596468
\n
<\/b>Mnemonic: ALSEN<\/b>\n<\/p>\n

\nDisclaimer<\/b>\n<\/p>\n

\nThis press release contains certain forward-looking statements concerning Sensorion and its business. Such forward looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the 2021 full year financial report published on April 28, 2022, and available on our website and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor Relations<\/b>
Catherine Leveau
\n
Head of Investor Relations & Communication
\n
+33 6 72 18 00 22
\n
ir.contact@sensorion-pharma.com<\/a><\/p>\n

International Media Relations<\/b>
Consilium Strategic Communications
\n
Mary-Jane Elliott\/Jessica Hodgson
\n
+44 7739 788014
\n
+44 7561 424788
\n
Sensorion@consilium-comms.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

MONTPELLIER, France–(BUSINESS WIRE)–Regulatory News: Sensorion (FR0012596468 \u2013 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, is pleased to announce the participation of members of Sensorion\u2019s management in three scientific conferences in July 2022. Laurent Desire, Ph.D., Sensorion\u2019s … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-45897","6":"format-standard","7":"category-industry"},"yoast_head":"\nSensorion to Present at the Gene Therapy Neurological Disorders Europe, CASSS Bioassays Symposium and Cell & Gene Therapy Summit Conferences in July 2022 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/sensorion-to-present-at-the-gene-therapy-neurological-disorders-europe-casss-bioassays-symposium-and-cell-gene-therapy-summit-conferences-in-july-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sensorion to Present at the Gene Therapy Neurological Disorders Europe, CASSS Bioassays Symposium and Cell & Gene Therapy Summit Conferences in July 2022 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"MONTPELLIER, France–(BUSINESS WIRE)–Regulatory News: Sensorion (FR0012596468 \u2013 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, is pleased to announce the participation of members of Sensorion\u2019s management in three scientific conferences in July 2022. Laurent Desire, Ph.D., Sensorion\u2019s ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/sensorion-to-present-at-the-gene-therapy-neurological-disorders-europe-casss-bioassays-symposium-and-cell-gene-therapy-summit-conferences-in-july-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-07T06:01:47+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sensorion-to-present-at-the-gene-therapy-neurological-disorders-europe-casss-bioassays-symposium-and-cell-gene-therapy-summit-conferences-in-july-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sensorion-to-present-at-the-gene-therapy-neurological-disorders-europe-casss-bioassays-symposium-and-cell-gene-therapy-summit-conferences-in-july-2022\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Sensorion to Present at the Gene Therapy Neurological Disorders Europe, CASSS Bioassays Symposium and Cell & Gene Therapy Summit Conferences in July 2022\",\"datePublished\":\"2022-07-07T06:01:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sensorion-to-present-at-the-gene-therapy-neurological-disorders-europe-casss-bioassays-symposium-and-cell-gene-therapy-summit-conferences-in-july-2022\\\/\"},\"wordCount\":791,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sensorion-to-present-at-the-gene-therapy-neurological-disorders-europe-casss-bioassays-symposium-and-cell-gene-therapy-summit-conferences-in-july-2022\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sensorion-to-present-at-the-gene-therapy-neurological-disorders-europe-casss-bioassays-symposium-and-cell-gene-therapy-summit-conferences-in-july-2022\\\/\",\"name\":\"Sensorion to Present at the Gene Therapy Neurological Disorders Europe, CASSS Bioassays Symposium and Cell & Gene Therapy Summit Conferences in July 2022 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2022-07-07T06:01:47+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sensorion-to-present-at-the-gene-therapy-neurological-disorders-europe-casss-bioassays-symposium-and-cell-gene-therapy-summit-conferences-in-july-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sensorion-to-present-at-the-gene-therapy-neurological-disorders-europe-casss-bioassays-symposium-and-cell-gene-therapy-summit-conferences-in-july-2022\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sensorion-to-present-at-the-gene-therapy-neurological-disorders-europe-casss-bioassays-symposium-and-cell-gene-therapy-summit-conferences-in-july-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sensorion to Present at the Gene Therapy Neurological Disorders Europe, CASSS Bioassays Symposium and Cell & Gene Therapy Summit Conferences in July 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sensorion to Present at the Gene Therapy Neurological Disorders Europe, CASSS Bioassays Symposium and Cell & Gene Therapy Summit Conferences in July 2022 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/sensorion-to-present-at-the-gene-therapy-neurological-disorders-europe-casss-bioassays-symposium-and-cell-gene-therapy-summit-conferences-in-july-2022\/","og_locale":"en_US","og_type":"article","og_title":"Sensorion to Present at the Gene Therapy Neurological Disorders Europe, CASSS Bioassays Symposium and Cell & Gene Therapy Summit Conferences in July 2022 - Pharma Trend","og_description":"MONTPELLIER, France–(BUSINESS WIRE)–Regulatory News: Sensorion (FR0012596468 \u2013 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, is pleased to announce the participation of members of Sensorion\u2019s management in three scientific conferences in July 2022. Laurent Desire, Ph.D., Sensorion\u2019s ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/sensorion-to-present-at-the-gene-therapy-neurological-disorders-europe-casss-bioassays-symposium-and-cell-gene-therapy-summit-conferences-in-july-2022\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-07T06:01:47+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/sensorion-to-present-at-the-gene-therapy-neurological-disorders-europe-casss-bioassays-symposium-and-cell-gene-therapy-summit-conferences-in-july-2022\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/sensorion-to-present-at-the-gene-therapy-neurological-disorders-europe-casss-bioassays-symposium-and-cell-gene-therapy-summit-conferences-in-july-2022\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Sensorion to Present at the Gene Therapy Neurological Disorders Europe, CASSS Bioassays Symposium and Cell & Gene Therapy Summit Conferences in July 2022","datePublished":"2022-07-07T06:01:47+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/sensorion-to-present-at-the-gene-therapy-neurological-disorders-europe-casss-bioassays-symposium-and-cell-gene-therapy-summit-conferences-in-july-2022\/"},"wordCount":791,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/sensorion-to-present-at-the-gene-therapy-neurological-disorders-europe-casss-bioassays-symposium-and-cell-gene-therapy-summit-conferences-in-july-2022\/","url":"https:\/\/pharma-trend.com\/en\/sensorion-to-present-at-the-gene-therapy-neurological-disorders-europe-casss-bioassays-symposium-and-cell-gene-therapy-summit-conferences-in-july-2022\/","name":"Sensorion to Present at the Gene Therapy Neurological Disorders Europe, CASSS Bioassays Symposium and Cell & Gene Therapy Summit Conferences in July 2022 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2022-07-07T06:01:47+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/sensorion-to-present-at-the-gene-therapy-neurological-disorders-europe-casss-bioassays-symposium-and-cell-gene-therapy-summit-conferences-in-july-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/sensorion-to-present-at-the-gene-therapy-neurological-disorders-europe-casss-bioassays-symposium-and-cell-gene-therapy-summit-conferences-in-july-2022\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/sensorion-to-present-at-the-gene-therapy-neurological-disorders-europe-casss-bioassays-symposium-and-cell-gene-therapy-summit-conferences-in-july-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Sensorion to Present at the Gene Therapy Neurological Disorders Europe, CASSS Bioassays Symposium and Cell & Gene Therapy Summit Conferences in July 2022"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45897","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=45897"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45897\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=45897"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=45897"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=45897"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}